The association of cancer ‐related fatigue with all‐cause mortality of colorectal and endometrial cancer survivors: Results from the population‐based PROFILES registry
Our study found that cancer ‐related fatigue is significantly associated with all‐cause mortality in male colorectal cancer survivors. This result suggests that clinicians should increase their attention towards the recognition and treatment of cancer‐related fatigue. AbstractPurposeCancer ‐related fatigue (CRF) is one of the most prevalent symptoms experienced by cancer survivors. However, researchers are only beginning to elucidate the risk factors, underlying mechanism(s), and its association with other outcomes. Research on the association between CRF and mortality is limited.MethodsThe study sample comprised 2059 short ‐term (
Source: Cancer Medicine - April 22, 2019 Category: Cancer & Oncology Authors: Salome Adam, Lonneke V. van de Poll ‐Franse, Floortje Mols, Nicole P. M. Ezendam, Ignace H. J. T. de Hingh, Volker Arndt, Melissa S. Y. Thong Tags: ORIGINAL RESEARCH Source Type: research

A comparison of risk factors for metastasis at diagnosis in humans and dogs with osteosarcoma
ConclusionA common mechanism may be driving trunk tumors to progress to detectable metastasis prior to diagnosis in both species. (Source: Cancer Medicine)
Source: Cancer Medicine - April 21, 2019 Category: Cancer & Oncology Authors: Brandon J. Diessner, Tracy A. Marko, Ruth M. Scott, Andrea L. Eckert, Kathleen M. Stuebner, Ann E. Hohenhaus, Kim A. Selting, David A. Largaespada, Jaime F. Modiano, Logan G. Spector Tags: ORIGINAL RESEARCH Source Type: research

Educational attainment of childhood cancer survivors: A systematic review
ConclusionThe literature does not provide a clear pattern of the long ‐term consequences of childhood cancer on education attainment. While this may suggest that there is no consistent difference between the education attainment of cancer survivors and controls, it may also be the result of limitations in the existing research. To better assess the education attainm ent of survivors, there is a need for high‐quality studies, with appropriate comparators, and standardized measures of education attainment across countries. (Source: Cancer Medicine)
Source: Cancer Medicine - April 21, 2019 Category: Cancer & Oncology Authors: Michal Molcho, Maureen D'Eath, Audrey Alforque Thomas, Linda Sharp Tags: REVIEW Source Type: research

Necessity of concurrent chemotherapy in N2 ‐3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity‐modulated radiotherapy
This study aims to evaluate the value of CCT in N2‐3 NPC when neoadjuvant chemotherapy (NACT) of sufficient cycles is performed to eradicate distant metastasis. It enrolled 959 patients d iagnosed with TxN2‐3M0 NPC from July 2011 to December 2015 and treated with NACT of 3‐4 cycles and IMRT. A propensity score matching (PSM) was made between patients treated with and without CCT (called the CCT and non‐CCT groups, respectively), using a series of clinical characteristics (age, gender, T stage, N stage, NACT regimen, and EBV DNA) as covariates. After PSM, the two groups of patients were compared on survivals and acu...
Source: Cancer Medicine - April 21, 2019 Category: Cancer & Oncology Authors: Hui Chang, Liang Peng, Ya ‐Lan Tao, Chen Chen, Wei‐Wei Xiao, Yong‐Hong Hu, Yuan‐Hong Gao Tags: ORIGINAL RESEARCH Source Type: research

Identification of a six ‐miRNA panel in serum benefiting pancreatic cancer diagnosis
In this study, we investigated miRNA expression levels in serum by qRT ‐PCR. The study was divided into four phases: the screening, training, testing, and external validation stage. We firstly chose candidate miRNAs using Exiqon panels in the screening phase. Then, a total of 129 PC serum samples and 107 normal controls (NCs) were further analyzed in the following tr aining and testing phases to identify differently expressed miRNAs. A cohort of 30 PC serum samples vs 30 NCs was used to confirm the diagnostic value of the identified miRNAs in the external validation phase. Moreover, miRNA expressions in additional 44 PC ...
Source: Cancer Medicine - April 21, 2019 Category: Cancer & Oncology Authors: Xuan Zou, Jishu Wei, Zebo Huang, Xin Zhou, Zipeng Lu, Wei Zhu, Yi Miao Tags: ORIGINAL RESEARCH Source Type: research

Fulvestrant in the treatment of hormone receptor ‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
This review summarizes the role and rationale of fulvestrant when used as a monotherapy or in combination with targeted therapies in patients with HR+/HER2 − advanced breast cancer. We also discuss other novel agents and potential future combination treatment options. AbstractNearly 75% of breast cancers are hormone receptor ‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the clinic, endocrine resistance (p...
Source: Cancer Medicine - April 19, 2019 Category: Cancer & Oncology Authors: Junjie Li, Zhonghua Wang, Zhimin Shao Tags: REVIEW Source Type: research

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women
We sought to examine associations in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR  = 1.4, 95% CI = 1.2‐1.7,P = 1.2 × 10−6, BFDP  = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4,P = 1.6 × 10−5, BFDP &n...
Source: Cancer Medicine - April 18, 2019 Category: Cancer & Oncology Authors: Delores J. Grant, Ani Manichaikul, Anthony J. Alberg, Elisa V. Bandera, Jill Barnholtz ‐Sloan, Melissa Bondy, Michele L. Cote, Ellen Funkhouser, Patricia G. Moorman, Lauren C. Peres, Edward S. Peters, Ann G. Schwartz, Paul D. Terry, Xin‐Q Tags: ORIGINAL RESEARCH Source Type: research

Effect of S ‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan
This study is aimed to compare the survival outcomes of patients with advanced pancreatic cancer treated with S ‐1 with the survival outcomes of those without S‐1 treatment before and after S‐1 reimbursement introduced in Taiwan in June of 2014. Our results support the clinical use of S‐1 as the treatment of choice for patients with locally advanced or metastatic pancreatic cancer, particularly in res ource‐limited situations. AbstractObjectiveStudies have rarely explored the efficacy of S ‐1 in treating advanced pancreatic cancer outside Japan. This study compared the survival outcomes of patients with advance...
Source: Cancer Medicine - April 18, 2019 Category: Cancer & Oncology Authors: Hsiang ‐Lan Lai, Yen‐Yang Chen, Chang‐Hsien Lu, Chia‐Yen Hung, Yung‐Chia Kuo, Jen‐Shi Chen, Hung‐Chih Hsu, Ping‐Tsung Chen, Pei‐Hung Chang, Yu‐Shin Hung, Wen‐Chi Chou Tags: ORIGINAL RESEARCH Source Type: research

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
In conclusion, the combination of hydroxyurea with ruxolitinib yielded a high clinical response rate and increased ruxolitinib exposure in patients with hyperproliferative forms of M F. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2019 Category: Cancer & Oncology Authors: Novella Pugliese, Claudia Giordano, Davide Nappi, Luigiana Luciano, Claudio Cerchione, Mario Annunziata, Beniamino Casale, Elena Cris à, Maria Rosaria Villa, Luca Pezzullo, Maria Iovine, Marco Picardi, Francesco Grimaldi, Fabrizio Pane, Vin Tags: ORIGINAL RESEARCH Source Type: research

Role of cytokines in combinatorial immunotherapeutics of non ‐small cell lung cancer through systems perspective
We have focused on the role of cytokines in combinatorial immunotherapeutics of non ‐small cell lung cancer (NSCLC), a major form of lung cancer. Through systems aspect, we are laying the concept of dissecting IL‐1b in future for therapeutic intervention. AbstractLung cancer is the leading cause of deaths related to cancer and accounts for more than a million deaths per year. Various new strategies have been developed and adapted for treatment; still the survival for 5 years is just 16% in patients with non ‐small cell lung cancer (NSCLC). Most of these strategies to combat NSCLC whether it is a drug molecule or immu...
Source: Cancer Medicine - April 17, 2019 Category: Cancer & Oncology Authors: Pragya Misra, Shailza Singh Tags: REVIEW Source Type: research

Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy
In conclusion, rs643555C >  T affectsCDH2 expression, and thus influences BCR in localized prostate cancer patients treated with RP.CDH2 rs643555 may be a promising biomarker to identify patients at high risk of poor prostate cancer prognosis. (Source: Cancer Medicine)
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Chia ‐Cheng Yu, Lih‐Chyang Chen, Victor C. Lin, Chao‐Yuan Huang, Wei‐Chung Cheng, Ai‐Ru Hsieh, Ta‐Yuan Chang, Te‐Ling Lu, Cheng‐Hsueh Lee, Shu‐Pin Huang, Bo‐Ying Bao Tags: ORIGINAL RESEARCH Source Type: research

SIRT3 elicited an anti ‐Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis
In this study, bioinformatics analyses were performed to identify the differentially expressed g enes and pathways enriched. CCA samples were collected for immunohistochemical analysis. Three human CCA cell lines (HuCCT1, RBE, and HCCC9810) were used to explore the molecular mechanism of SIRT3 regulation of metabolic reprogramming and malignant behavior in CCA. A CCA xenograft model was then es tablished for further validation in vivo. The data showed that SIRT3 expression was decreased and glycolysis was enhanced in CCA. Similar metabolic reprogramming was also observed in SIRT3 knockout mice. Furthermore, we demonstrated...
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Lei Xu, Yang Li, Lixing Zhou, Robert Gregory Dorfman, Li Liu, Rui Cai, Chenfei Jiang, Dehua Tang, Yuming Wang, Xiaoping Zou, Lei Wang, Mingming Zhang Tags: ORIGINAL RESEARCH Source Type: research

Expression of immune checkpoint receptors Indoleamine 2,3 ‐dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma
Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain is increased in primary choroidal melanomas from patients that later develop metastases. This may be a future target for adjuvant therapy with checkpoint inhibitors. AbstractBackgroundSurvival in metastasized cutaneous melanoma (CM) has been improved with the advent of inhibitors of immune checkpoints CTLA4 and PD ‐1. In contrast, the response rate for inhibition of these checkpoints in uveal melanoma (UM) is very low. Other checkpoints including IDO and TIGIT may be targetable.MethodsSections from 6 patients with UM, who ...
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Gustav St ålhammar, Stefan Seregard, Hans E. Grossniklaus Tags: ORIGINAL RESEARCH Source Type: research

Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases
ConclusionsIn men with T2D but without CLD nor metformin use, HCC incidence was lower for NHAA compared to NHW or Hispanics; similar between NHW and Hispanics. Metformin use reduced HCC risk and modified the race/ethnicity disparity.ImpactMetformin's heterogeneous HCC prevention effect elucidates potential interventions to modify HCC disparity in patients with T2D. (Source: Cancer Medicine)
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Chen ‐Pin Wang, John Kuhn, Dimpy P. Shah, Susanne Schmidt, Yui‐Wing F. Lam, Daniel MacCarthy, Laura Tenner, Amelie G. Ramirez Tags: ORIGINAL RESEARCH Source Type: research

Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer
AberrantGasdermin E (GSDME) methylation in cancer makes it a candidate biomarker gene. This is the first study to thoroughly analyzeGSDME methylation in the largest colorectal adenocarcinoma patient cohort to date (N  = 432) using publicly available data. We identified a combination of CpGs, that can discriminate between colorectal cancer and normal tissue samples with high accuracy (AUC = 0.95). Additionally, we found significant differences inGSDME methylation between left ‐ and right‐sided colorectal cancers. AbstractIn addition to its implication in hereditary hearing loss, theGasdermin E (GSDME...
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Joe Ibrahim, Ken Op de Beeck, Erik Fransen, Lieselot Croes, Matthias Beyens, Arvid Suls, Wim Vanden Berghe, Marc Peeters, Guy Camp Tags: ORIGINAL RESEARCH Source Type: research

Impact of the relative dose intensity on survival of patients with high ‐risk myelodysplastic syndromes treated with Azacitidine
Myelodysplastic syndromes patients receiving Azacitidine and who had dose reduction before achieving the objective response had significantly lower overall survivals and progression ‐free survivals compared to patients who had dose reduction after achieving the objective response, and we strongly recommend that this should be taken in high consideration when proceeding to dose reduction. AbstractWe performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high ‐risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI)
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Kamel Laribi, Delphine Bolle, Mustafa Alani, Habib Ghnaya, Anne Besan çon, Jonathan Farhi, Kayane Mheidly, Nathalie Denizon, Alix Baugier de Materre Tags: ORIGINAL RESEARCH Source Type: research

HPV ‐vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level
Countries with high income, adopting vaccination and screening programs, have low incidence and mortality rates respect to those with lower ‐middle income. Eastern European and Asian Countries have lower‐middle income and show high incidence and mortality rates, indicating poor attention to prevention (primary and secondary). AbstractHuman papillomavirus (HPV) is the most common sexually transmitted disease in the world. The aim of our study is to describe the differences in HPV ‐vaccination coverage and screening programs in WHO European Countries notably according to income levels. Multiple correspondence analysis ...
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Emma Altobelli, Leonardo Rapacchietta, Valerio F. Profeta, Roberto Fagnano Tags: ORIGINAL RESEARCH Source Type: research

The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non ‐small‐cell lung cancer‐a retrospective study from one single cancer institute
ConclusionsOur results suggest that patients with good performance statuses, non ‐smoking patients, and the administration of EGFR‐TKIs might improve clinical outcomes in NSCLC patients with LM. (Source: Cancer Medicine)
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Weiwei Yan, Wang Jing, Ning An, Yaru Tian, Dong Guo, Li Kong, Hui Zhu, Jinming Yu Tags: ORIGINAL RESEARCH Source Type: research

Intraoperative quantification of meningioma cell proliferation potential using rapid flow cytometry reveals intratumoral heterogeneity
Intraoperative rapid and quantitative flow cytometry was conducted to assess the proliferative ability of meningioma cells. This highly quantitative method revealed the intratumoral heterogeneity of cellular proliferative potential in meningiomas. AbstractBackgroundStandard sampling methods to evaluate the proliferative ability of meningioma have not been established.MethodsThis prospective study was conducted to evaluate the effectiveness of intraoperative rapid flow cytometry (iFC) using raw samples for the quantitative assessment of proliferative ability in meningioma cells and to investigate intratumoral heterogeneity....
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Soichi Oya, Shinsuke Yoshida, Tsukasa Tsuchiya, Naoaki Fujisawa, Akitake Mukasa, Hirofumi Nakatomi, Nobuhito Saito, Toru Matsui Tags: ORIGINAL RESEARCH Source Type: research

Mortality of lung cancer as a second primary malignancy: A population ‐based cohort study
This study aims to examine the overall and cancer‐specific survival of patients diagnosed with lung‐2 compared to lung‐1. Primary lung cancer patients diagnosed from 1988 to 2014 in the Surveillance, Epidemiology, and End Re sults (SEER) program were included. Lung‐2 was identified in patients with a previous diagnosis of nonlung primary malignancy in SEER. Hazard ratios (HRs) of overall and lung cancer‐specific mortality were estimated among patients with lung‐2 compared to lung‐1, adjusting for age and calenda r period at diagnosis, sex, race, socioeconomic status, tumor stage, histology, tumor grade, and t...
Source: Cancer Medicine - April 16, 2019 Category: Cancer & Oncology Authors: Lei Deng, Hr önn Harðardottír, Huan Song, Zhengrui Xiao, Changchuan Jiang, Qian Wang, Unnur Valdimarsdóttir, Haiying Cheng, Billy W. Loo, Donghao Lu Tags: ORIGINAL RESEARCH Source Type: research

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre ‐ibrutinib era: Incidence and risk factors
This study included 24  198 CLL patients treated in the VA system before FDA approval of ibrutinib as CLL therapy. Data came from VA databases from 1999 to 2013. MH incidence was 1.9/100 person‐years (95% CI: 1.8‐1.9), with cumulative incidences of 2.3%, 5.2%, and 7.3% by year 1, 3, and 5, respectively. Median time f rom CLL diagnosis to MH was 2.8 years (range: 0‐15.7 years). In multivariate analyses, concurrent anticoagulant and antiplatelet use (HR: 4.2; 95% CI: 3.2‐5.6), anticoagulant use only (HR: 2.6; 95% CI: 2.3‐3.1), and antiplatelet use only (HR: 1.5; 95% CI: 1.3‐1.7) increased MH risk v...
Source: Cancer Medicine - April 14, 2019 Category: Cancer & Oncology Authors: Peter Georgantopoulos, Huiying Yang, LeAnn B. Norris, Charles L. Bennett Tags: ORIGINAL RESEARCH Source Type: research

Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy
ConclusionsHT Dmax, WB Dmin, and WB Dmean are promising indicators of lymphopenia and the survival of glioma patients undergoing postoperative IMRT. The necessity and feasibility of dosimetric constraints for HT and WB is warranted with further investigation. (Source: Cancer Medicine)
Source: Cancer Medicine - April 14, 2019 Category: Cancer & Oncology Authors: Lu ‐Lu Ye, Xing‐Wen Fan, Chao‐Su Hu, Xia‐Yun He, Xiao‐Shen Wang, Chun‐Ying Shen, Ting‐Ting Xu, Hong‐Mei Ying Tags: ORIGINAL RESEARCH Source Type: research

Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma
Our study reveals that red blood cell distribution width (RDW)  is an independent prognostic factor in patients with mantle cell lymphoma, and RDW refines the prognostic stratification based on simplified Mantle Cell International Prognostic Index. More importantly, RDW is a marker of clinical feasibility. Therefore, RDW can be used as a novel prognostic facto r in mantle cell lymphoma. AbstractRed blood cell distribution width (RDW), which measures the range of variation of red blood cell volume, has been explored as a prognostic factor in multiple types of cancer. However, the role of RDW in mantle cell lymphoma (MC...
Source: Cancer Medicine - April 13, 2019 Category: Cancer & Oncology Authors: Yi Miao, Xiao-Hui Zhou, Jing-Jing Guo, Qian Sun, Ke Shi, Jia ‐Zhu Wu, Hua‐Yuan Zhu, Li Wang, Lei Fan, Wei Xu, Jian‐Yong Li Tags: ORIGINAL RESEARCH Source Type: research

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes
This paper mainly aims to figure out the multiple ‐gene panel revealed mutational characteristics of breast cancer susceptibility genes in 481 Chinese women with familial breast cancer history.  AbstractGenetic testing for germline mutations inBRCA1/2 of patients with breast cancer (BC) is part of routine patient care. However,BRCA1/2 mutations account only for a fraction of familial BC. A custom panel of 22 gene sequencing was performed on each patient. Among the 481 female patients, 135 patients were detected to carry pathogenic (P)/likely pathogenic (LP) mutations (28.1%), which corresponded to 12 different can...
Source: Cancer Medicine - April 13, 2019 Category: Cancer & Oncology Authors: Jiayu Wang, Weiwei Li, Yujian Shi, Yan Huang, Tao Sun, Lili Tang, Qing Lu, Qiumo Lei, Ning Liao, Feng Jin, Hui Li, Tao Huang, Jun Qian, Danmei Pang, Shusen Wang, Peizhi Fan, Xinhong Wu, Ying Lin, Haiyan Qin, Binghe Xu Tags: ORIGINAL RESEARCH Source Type: research

Can acetylcysteine ameliorate cisplatin ‐induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double‐blind, placebo‐controlled trial involving patients with head and neck cancer
The use of antioxidants, such as acetylcysteine, in patients receiving chemotherapy is currently a hot topic in the literature. There are no studies in humans to verify the effect of acetylcysteine on toxicity, oxidative stress, and clinical response to cisplatin. This is the first randomized, double ‐blind, placebo‐controlled trial to investigate this issue. AbstractThe protective antioxidant activity of acetylcysteine (NAC) against toxicity due to cisplatin has been reported in experimental models; however, its efficacy in patients has not been elucidated. The aim of this study was to investigate the possible protect...
Source: Cancer Medicine - April 11, 2019 Category: Cancer & Oncology Authors: Mar ília B. Visacri, Júlia C. F. Quintanilha, Vanessa M. de Sousa, Laís S. Amaral, Rosiane de F. L. Ambrósio, Luciane Calonga, Silvia F. B. B. Curi, Mayra F. de T. Leme, Carlos T. Chone, João M. C. Altemani, Priscila G. Mazzola, Carina Mal Tags: ORIGINAL RESEARCH Source Type: research

Hyperammonemia after capecitabine associated with occult impairment of the urea cycle
ConclusionsCapecitabine and 5 ‐fluorouracil inhibit pyrimidine biosynthesis, decreasing ammonia utilization. These drugs can induce hyperammonemia in susceptible individuals. The risk factors of hyperammonemia, gene mutations and liver dysfunction, are not rare. Diagnosis will trigger appropriate treatment and ameliorate brain toxicity. (Source: Cancer Medicine)
Source: Cancer Medicine - April 11, 2019 Category: Cancer & Oncology Authors: Gilbert Chu, Julia Salzman Tags: ORIGINAL RESEARCH Source Type: research

Epidermal growth factor ‐containing fibulin‐like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B)
ConclusionIn summary, our research revealed the regulation of EFEMP1 on cell proliferation and apoptosis in HCC. EFEMP1 may suppress the growth of HCC cells by promoting SEMA3B. (Source: Cancer Medicine)
Source: Cancer Medicine - April 11, 2019 Category: Cancer & Oncology Authors: Jiangfeng Hu, Bensong Duan, Weiliang Jiang, Sengwang Fu, Hengjun Gao, Lungen Lu Tags: ORIGINAL RESEARCH Source Type: research

Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk
ConclusionsOur data suggest that VitD deficiency could be a biomarker for poor response to cisplatin, and pretreating with VitD can increase the apoptotic response to cisplatin through VDR and TAp73 signaling crosstalk. (Source: Cancer Medicine)
Source: Cancer Medicine - April 10, 2019 Category: Cancer & Oncology Authors: Brittany L. Bunch, Yingyu Ma, Kristopher Attwood, Lauren Amable, Wei Luo, Carl Morrison, Khurshid A. Guru, Anna Woloszynska ‐Read, Pamela A. Hershberger, Donald L. Trump, Candace S. Johnson Tags: ORIGINAL RESEARCH Source Type: research

Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation
In this study, we demonstrate that ACO2 expression positively correlates with prostate cancer malignancy and drug resistance. In addition, we found that p53 decreases SIRT3 expression and zinc increases the production of hydroxyl radicals, which lead to an increase in reactive oxygen species (ROS). Furthermore, accumulated ROS causes a decrease in ACO2 activity, which leads to mitochondrial dysfunction and results in apoptosis. Thus, ACO2 can be a target for remodeling metabolism by sensing changes in ROS of prostate cancer cells, and targeting ACO2 through zinc and p53 to change the metabolic pattern of malignant cells ca...
Source: Cancer Medicine - April 10, 2019 Category: Cancer & Oncology Authors: Ya ‐Nan Xue, Ya‐Nan Liu, Jing Su, Jiu‐Ling Li, Yao Wu, Rui Guo, Bing‐Bing Yu, Xiao‐Yu Yan, Li‐Chao Zhang, Lian‐Kun Sun, Yang Li Tags: ORIGINAL RESEARCH Source Type: research

Circulating PD ‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
These figures showed that the gene expression of PD ‐1 (+) cells in peripheral blood of PTCL patients was different from that of healthy controls (Figures#cam42097-fig-0001 and#cam42097-fig-0002), and anti ‐tumor effects of PD‐1 (+) cells were weaker than that of PD‐1 (‐) cells (Figures#cam42097-fig-0003 and#cam42097-fig-0004), while chidamide could normalize tumor immunity by regulating immune ‐associated genes of PD‐1 (+) cells (Fig. 5). AbstractPeripheral T ‐cell lymphoma (PTCL) is a heterogeneous disease with poor outcomes. We intend to explore the role of circulating PD‐1 (+) cells in tumor immune ev...
Source: Cancer Medicine - April 10, 2019 Category: Cancer & Oncology Authors: Wei Zhang, Haorui Shen, Yan Zhang, Wei Wang, Shaoxuan Hu, Dongmei Zou, Daobin Zhou Tags: ORIGINAL RESEARCH Source Type: research

Gene amplification derived a cancer ‐testis long noncoding RNA PCAT6 regulates cell proliferation and migration in hepatocellular carcinoma
Our data demonstrated that CT ‐lncRNA PCAT6 represents the similarity and difference between tumorigenesis and gametogenesis. The CT expression pattern and important role in LIHC oncogenesis make PCAT6 an ideal target for LIHC diagnosis and therapy. AbstractOur previous work demonstrated cancer ‐testis (CT) genes as a new source of candidate driver of cancer. Recently, mounting evidence indicates that long noncoding RNAs (lncRNAs) with CT expression pattern could play a pivotal role in cancer biology. Here, we characterized a conserved CT long noncoding RNA (CT‐lncRNA),PCAT6, which is expressed exclusively in the tes...
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Shuaizhou Chen, Yao Chen, Qufei Qian, Xuewei Wang, Yuting Chang, Sihan Ju, Yide Xu, Chang Zhang, Na Qin, Hui Ding, Yayun Gu, Jing Han, Cheng Wang, Erbao Zhang, Zhibin Hu Tags: ORIGINAL RESEARCH Source Type: research

Fixed combination of oral NEPA (netupitant ‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
The efficacy of oral NEPA (netupitant ‐palonosetron 300/0.50 mg) was evaluated from two randomized phase III studies in patients receiving HEC, AC, or MEC over multiple chemotherapy cycles. Oral NEPA had significantly higher CR, no emesis, and NSN rates than oral PALO and numerically higher CR and NSN rates than oral APR‐PALO. Oral NEPA effectively prevented both acute and delayed CINV over multiple chemotherapy cycles of HEC, AC, and MEC. AbstractAimTo assess the efficacy of oral NEPA (netupitant ‐palonosetron 300/0.50 mg) over multiple chemotherapy cycles.MethodsTwo randomized phase III studies evaluated ...
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Lee Schwartzberg, Meinolf Karthaus, Giorgia Rossi, Giada Rizzi, Maria E. Borroni, Hope S. Rugo, Karin Jordan, Vincent Hansen Tags: ORIGINAL RESEARCH Source Type: research

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population ‐based cohort study
In conclusion, both metformin medication and TCM use could be associated with reduced risk of prostate cancer for men with BPH and diabetes. (Source: Cancer Medicine)
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Yu ‐Jui Kuo, Fung‐Chang Sung, Po‐Fan Hsieh, Hui‐Ping Chang, Kun‐Ling Wu, Hsi‐Chin Wu Tags: ORIGINAL RESEARCH Source Type: research

Acute kidney injury predicts all ‐cause mortality in patients with cancer
In this study, AKI was an independent risk factor for all ‐cause mortality in overall cancer patients with dose‐responsive manner. AbstractBackgroundAcute kidney injury (AKI) is a critical issue in cancer patients because it is not only a morbid complication but also able to interrupt timely diagnostic evaluation or planned optimal treatment. However, the impact of AKI on overall mortality in cancer patients remains unclear.MethodsWe conducted a retrospective cohort study of 67  986 cancer patients, from 2004 to 2013 to evaluate the relationship between AKI and all‐cause mortality. We used KDIGO AKI definition a...
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Eunjeong Kang, Minsu Park, Peong Gang Park, Namyong Park, Younglee Jung, U Kang, Hee Gyung Kang, Dong Ki Kim, Kook ‐Hwan Oh, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee Tags: ORIGINAL RESEARCH Source Type: research

Comparing high ‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
ConclusionsWeekly CP regimen can serve as an alternative systemic therapy with radiation in patients with LAHNSCC who are not fit for Cis. (Source: Cancer Medicine)
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Muhammad Furqan, Travis P. Snyders, Mohammed U. Saqlain, Sarah L. Mott, Douglas Laux, Anthony Snow, Carryn M. Anderson, John M. Watkins, Gerald H. Clamon Tags: ORIGINAL RESEARCH Source Type: research

Systematic evaluation of cancer ‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts
Genetic risk score (GRS) is an odds ratio (OR) ‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated SNPs. Validity of GRS for predicting cancer risk is demonstrated for most types of cancer. If confirmed in larger studies, cancer‐specific GRS may have potential for developing personaliz ed cancer screening strategy. AbstractBackgroundGenetic risk score (GRS) is an odds ratio (OR) ‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). We hypothesize that GRS is a valid t...
Source: Cancer Medicine - April 9, 2019 Category: Cancer & Oncology Authors: Zhuqing Shi, Hongjie Yu, Yishuo Wu, Xiaoling Lin, Quanwa Bao, Haifei Jia, Chelsea Perschon, David Duggan, Brian T. Helfand, Siqun L. Zheng, Jianfeng Xu Tags: ORIGINAL RESEARCH Source Type: research

Protein arginine methyltransferase 5: A novel therapeutic target for triple ‐negative breast cancers
Alternatives to current treatments are direly needed for patients with triple ‐negative breast cancers (TNBC). The present study endorses PRMT5 as a novel therapeutic target in TNBC. PRMT5 pharmacological inhibition decreases viability in a subset of TNBC cell lines, mitigates early‐stage tumor progression in vivo, and displays additive/synergistic effects in combination with EGFR inhibition. Importantly, this study shows distinctive PRMT5 subcellular localization in TNBC, underlining the importance of site‐specific PRMT5 activity in the context of breast cancers. AbstractTNBC is a highly heterogeneous and aggressive...
Source: Cancer Medicine - April 8, 2019 Category: Cancer & Oncology Authors: Mathilde Vinet, Samyuktha Suresh, Virginie Maire, Clarisse Monchecourt, Fariba N émati, Laetitia Lesage, Fabienne Pierre, Mengliang Ye, Auriane Lescure, Amélie Brisson, Didier Meseure, André Nicolas, Guillem Rigaill, Elisabetta Marangoni, Tags: ORIGINAL RESEARCH Source Type: research

TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma
We report that TLR4 ‐AKT signaling pathway is activated by lipopolysaccharides (LPS) to enhance the stemness capacity of HCC. AbstractToll ‐like receptor 4 (TLR4) plays an essential role in cancer progress. Here, we find that the expression of TLR4 in relapsed human hepatocellular carcinoma (HCC) clinical samples is higher than that in the non‐relapsed ones, which leads us to explore the role of TLR4 in cancer stemness. We reported that TLR4‐AKT signaling pathway was activated by lipopolysaccharides (LPS) in HCC cell lines to enhance the cancer stemness capacity, which was reflected by the increased percentage of C...
Source: Cancer Medicine - April 8, 2019 Category: Cancer & Oncology Authors: Shuang Zhou, Renle Du, Zhenglu Wang, Wenzhi Shen, Ruifang Gao, Shan Jiang, Yan Fang, Yuzhi Shi, Antao Chang, Lei Liu, Chenghu Liu, Na Li, Rong Xiang Tags: ORIGINAL RESEARCH Source Type: research

LukS ‐PV induces apoptosis in acute myeloid leukemia cells mediated by C5a receptor
LukS ‐PV can induce apoptosis in acute myeloid leukemia (AML) cells through C5a receptor (C5aR), implicating C5aR as a potential target and LukS‐PV as a targeted drug for the treatment of AML AbstractLukS ‐PV is one of the two components of Panton‐Valentine leucocidin (PVL). Our previous study showed that LukS‐PV can induce apoptosis in human acute myeloid leukemia (AML) THP‐1 and HL‐60 cells. C5aR (C5a receptor) is the receptor for PVL, but whether C5aR plays a key role in LukS‐PV induce d apoptosis is unclear. The aim of this study was to establish whether C5aR plays a physiological role in apoptosis of l...
Source: Cancer Medicine - April 6, 2019 Category: Cancer & Oncology Authors: Peng Zhang, Wen ‐Wei Yu, Jing Peng, Liang‐Fei Xu, Chang‐Cheng Zhao, Wen‐Jiao Chang, Xiao‐Ling Ma Tags: ORIGINAL RESEARCH Source Type: research

Occupational class differences in pancreatic cancer survival: A population ‐based cancer registry‐based study in Japan
ConclusionWe documented occupational class disparities in pancreatic cancer survival in Japan. Even in the setting of lethal prognostic cancer with universal health coverage, high ‐occupational class groups may enjoy a health advantage. (Source: Cancer Medicine)
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Masayoshi Zaitsu, Yongjoo Kim, Hye ‐Eun Lee, Takumi Takeuchi, Yasuki Kobayashi, Ichiro Kawachi Tags: ORIGINAL RESEARCH Source Type: research

Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration
ConclusionsWe used the TDF to identify several behavioral domains acting as determinants of high ‐quality, team‐based prostate cancer survivorship care. These results can inform prostate cancer survivorship care plan content, and may guide tailored, multidisciplinary implementation strategies to improve survivorship care across the primary and specialty care interface. (Source: Cancer Medicine)
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Archana Radhakrishnan, Jennifer Henry, Kevin Zhu, Sarah T. Hawley, Brent K. Hollenbeck, Timothy Hofer, Daniela A. Wittmann, Anne E. Sales, Ted A. Skolarus Tags: ORIGINAL RESEARCH Source Type: research

Prognostic implications of a molecular classifier derived from whole ‐exome sequencing in nasopharyngeal carcinoma
We proposed three prominent NPC genetic subtypes: RAS/PI3K/AKT, cell ‐cycle, and unclassified using the whole‐exome sequencing. Survival analysis indicated that there were statistically significant among patients with three subgroups. This result reflects the genetic alterations of NPC with distinct mutations and/or copy number changes and provides a roadmap for developing new prognostic biomarkers and targeted therapies. AbstractThe aim of this study was to use whole ‐exome sequencing to derive a molecular classifier for nasopharyngeal carcinoma (NPC) and evaluate its clinical performance. We performed whole‐exome...
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Hai ‐Yun Wang, Fugen Li, Na Liu, Xiao‐Yun Liu, Xin‐Hua Yang, Yun‐Miao Guo, Jin‐Xin Bei, Yi‐Xin Zeng, Jian‐Yong Shao Tags: ORIGINAL RESEARCH Source Type: research

Travel burden associated with rare cancers: The example of Merkel cell carcinoma
This study evaluated the travel burden of patients with Merkel cell carcinoma (MCC), a rare cancer, enrolled in a cancer registry at a large cancer center and found that the majority of MCC patients traveled long distances to receive expert care. Longer travel distances appeared to be associated with younger age, a more advanced stage of cancer at study entry and fewer in ‐clinic visits, suggesting that travel burden may impact timely and adequate patient care for this rare cancer. P25, 25th percentile; P75, 75th percentile AbstractBackgroundThere are limited data on the travel burden for cancer patients with rare tumor ...
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Rahul Jain, Joseph Menzin, Kristina Lachance, Patrick McBee, Hemant Phatak, Paul T. Nghiem Tags: ORIGINAL RESEARCH Source Type: research

Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
In this report, we reviewed the major advantages, challenges, and prospective directions for combination of conventional methods and bacteria for tumor therapy. AbstractSuccessful treatment of cancer remains a challenge, due to the unique pathophysiology of solid tumors, and the predictable emergence of resistance. Traditional methods for cancer therapy including radiotherapy, chemotherapy, and immunotherapy all have their own limitations. A novel approach is bacteriotherapy, either used alone, or in combination with conventional methods, has shown a positive effect on regression of tumors and inhibition of metastasis. Bac...
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Mansour Sedighi, Abed Zahedi Bialvaei, Michael R. Hamblin, Elnaz Ohadi, Arezoo Asadi, Masoumeh Halajzadeh, Vahid Lohrasbi, Nima Mohammadzadeh, Taghi Amiriani, Marcela Krutova, Abolfazl Amini, Ebrahim Kouhsari Tags: REVIEW Source Type: research

Association of sociodemographic and oncological features with decision on implant ‐based versus autologous immediate postmastectomy breast reconstruction in Chinese patients
ConclusionsThe sociodemographic and oncological features are directly or indirectly associated with the decision on type of IPBR. The findings may facilitate both patients and physicians to make a high ‐quality decision by holistic evaluation of the sociodemographic and oncological features. (Source: Cancer Medicine)
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Zhuming Yin, Yan Wang, Jingyan Sun, Qingfeng Huang, Jing Liu, Shanshan He, Chunyong Han, Shu Wang, Bowen Ding, Jian Yin Tags: ORIGINAL RESEARCH Source Type: research

Prospective validation of the prognostic 31 ‐gene expression profiling test in primary cutaneous melanoma
Current prognostic methods have limitations and may underestimate metastatic risk of early ‐stage melanoma. In a prospective, single institution cohort of patients undergoing sentinel node biopsy, the 31‐gene expression profile test for melanoma was an independent predictor of recurrence and metastasis and has additive prognostic utility in initial melanoma work‐up. AbstractBackgroundGene expression profiling (GEP) has been integrated into cancer treatment decision ‐making in multiple neoplasms. We prospectively evaluated the prognostic utility of the 31‐GEP test (DecisionDx‐Melanoma, Castle Biosciences, Inc) i...
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Jennifer Keller, Theresa L. Schwartz, Jason M. Lizalek, Ea ‐sle Chang, Ashaki D. Patel, Maria Y. Hurley, Eddy C. Hsueh Tags: ORIGINAL RESEARCH Source Type: research

Risk of immune ‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
ConclusionsThis study demonstrates that compared with chemotherapy, PD ‐1 inhibitor may result in a higher risk of immune‐related pneumonitis. Nivolumab plus ipilimumab therapy had the highest pneumonitis risk. These findings could be taken into account by the physicians in decision making. (Source: Cancer Medicine)
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Yafang Huang, Haiyu Fan, Ning Li, Juan Du Tags: ORIGINAL RESEARCH Source Type: research

Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta ‐analysis
Cyclin D2/D3 (CCND2/3) are core components of the machinery that drives cell cycle progression and associated with tumorigenesis. This meta ‐analysis indicated CCND2/3 could be promising biomarkers for predicting the prognosis of patients with malignant neoplasms. AbstractCyclin D2/D3 (CCND2/3) are core components of the machinery that drives cell cycle progression and therefore, are associated with tumorigenesis. Currently, there are contradictory evidences on the function of CCND2/3 in tumorigenesis. Thus, we conducted a comprehensive meta ‐analysis to derive a precise predictive value of CCND2/3 in various tumors. W...
Source: Cancer Medicine - April 5, 2019 Category: Cancer & Oncology Authors: Zuo ‐you Ding, Ran Li, Qi‐jie Zhang, Yi Wang, Yi Jiang, Qing‐yang Meng, Qiu‐lei Xi, Guo‐hao Wu Tags: ORIGINAL RESEARCH Source Type: research

The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity ‐modulated radiotherapy era
ConclusionsIn the IMRT era, three T categories are more reasonable (merging T2/T3 into T2) and proT3N0 ‐2 (the 8th edition T4N0‐2) should be down‐staged to stage III. (Source: Cancer Medicine)
Source: Cancer Medicine - April 4, 2019 Category: Cancer & Oncology Authors: Ling ‐Long Tang, Shao‐Bo Liang, Cheng‐Long Huang, Fan Zhang, Cheng Xu, Yan‐Ping Mao, Li Tian, Ai‐Hua Lin, Li Li, Ying Sun, Jun Ma Tags: ORIGINAL RESEARCH Source Type: research

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
In this study, we compared the accuracy of digital PCR (dPCR) and RT ‐qPCR for BCR‐ABL1 transcript levels detection by monitoring 142 CML patients for a median time of 24 months. The clinical and hematological characteristics of the patients grouped according to DMR classes (MR4.0 vs MR4.5 ‐5.0) were superimposable, while patients with dPCR values
Source: Cancer Medicine - April 4, 2019 Category: Cancer & Oncology Authors: Simona Bernardi, Michele Malagola, Camilla Zanaglio, Nicola Polverelli, Elif Dereli Eke, Mariella D ’Adda, Mirko Farina, Cristina Bucelli, Luigi Scaffidi, Eleonora Toffoletti, Clara Deambrogi, Fabio Stagno, Micaela Bergamaschi, Luca Frances Tags: ORIGINAL RESEARCH Source Type: research